ChemoCentryx to Present at Two Upcoming Investor Conferences
April 03 2018 - 8:30AM
ChemoCentryx, Inc., (Nasdaq:CCXI), today announced that Thomas J.
Schall, Ph.D., President and Chief Executive Officer, will present
at two upcoming investor conferences in April:
- H.C. Wainwright Global Life Sciences
ConferenceMonday, April 9, 2018 at 9:00 a.m. Central
European TimeLe Meridien Beach Plaza Hotel, Monaco
- Jefferies 2018 Complement Therapeutics
SummitTuesday, April 10, 2018 at 9:30 a.m. Eastern TimeNew
York, NY
A live audio webcast of the presentation at the H.C. Wainwright
Global Life Sciences Conference can be accessed through the
Investors section of the Company's website at www.ChemoCentryx.com.
A replay of the webcast will be available on the Company's website
for two weeks following the live presentation.
About ChemoCentryx
ChemoCentryx is a biopharmaceutical company developing new
medications targeted at inflammatory and autoimmune diseases and
cancer. ChemoCentryx targets the chemokine and chemoattractant
systems to discover, develop and commercialize orally-administered
therapies. ChemoCentryx is currently focusing on its late stage
drug candidates for patients with rare kidney diseases, avacopan
(CCX168) and CCX140.
Avacopan is an orally-administered small molecule that is a
selective inhibitor of the complement C5a receptor, or C5aR.
Avacopan is in Phase III development for the treatment of
anti-neutrophil cytoplasmic auto-antibody-associated vasculitis
(ANCA Vasculitis). In clinical studies to date, avacopan was shown
to be safe, well tolerated and provided effective control of the
disease while allowing elimination of high-dose steroids, part of
the current standard of care. Avacopan is also being developed in
patients with C3 glomerulopathy (C3G), hidradenitis suppurativa
(HS) and atypical hemolytic uremic syndrome (aHUS). The U.S. Food
and Drug Administration has granted avacopan orphan-drug
designation for ANCA Vasculitis, C3G and aHUS. The European
Commission has granted orphan medicinal product designation for
avacopan for the treatment of two forms of ANCA Vasculitis:
microscopic polyangiitis and granulomatosis with polyangiitis
(formerly known as Wegener's granulomatosis), as well as for C3G.
Avacopan was also granted access to the European Medicines Agency's
(EMA) PRIority MEdicines (PRIME) initiative, which supports
accelerated assessment of investigational therapies addressing
unmet medical need.
The Company's other late stage drug candidate is CCX140, an
inhibitor of the chemokine receptor known as CCR2, which is
currently being developed for patients with focal segmental
glomerulosclerosis (FSGS), a debilitating kidney disease.
ChemoCentryx's Kidney Health Alliance with Vifor Pharma provides
Vifor Pharma with exclusive rights to commercialize avacopan and
CCX140 in markets outside of the U.S. and China.
ChemoCentryx also has early stage drug candidates that target
chemoattractant receptors in other Inflammatory and autoimmune
diseases and in cancer.
Source: ChemoCentryx, Inc.
CCXI-G
Contacts:
Susan M.
Kanaya
Executive Vice President, Chief Financial and Administrative
Officer
investor@chemocentryx.com
Media:Stephanie Tomei408.234.1279media@chemocentryx.com
Investors:Burns McClellan, Inc. Steve
Klass212.213.0006
sklass@burnsmc.com
ChemoCentryx (NASDAQ:CCXI)
Historical Stock Chart
From Aug 2024 to Sep 2024
ChemoCentryx (NASDAQ:CCXI)
Historical Stock Chart
From Sep 2023 to Sep 2024